No Data
No Data
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully
Express News | RenovoRx Increases Production of FDA-Cleared Renovocath® Delivery System in Response to Strong Demand From Oncology and Interventional Radiology Physicians
RenovoRx Announces Presentation At Symposium On Clinical Interventional Oncology Highlighting TAMP For Targeted Treatment Of Locally Advanced Pancreatic Cancer On Saturday, September 21, 2024
Express News | RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting Tamp™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
Ascendiant Maintains RenovoRx(RNXT.US) With Buy Rating, Raises Target Price to $8.25
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
No Data
No Data